Colony-stimulating factors for the management of neutropenia in cancer patients

Drugs

Volumn 62, Issue SUPPL. 1, 2002, Pages 1-15

  Dale, David C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINCRISTINE; FILGRASTIM;

ACUTE GRANULOCYTIC LEUKEMIA; ANAMNESIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL COUNT; CLINICAL TRIAL; COMORBIDITY; CROHN DISEASE; DIABETIC FOOT; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG INDICATION; DRUG POTENCY; EDEMA; FEBRILE NEUTROPENIA; FEVER; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFECTION RISK; LYMPHATIC LEUKEMIA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL; PNEUMONIA; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SALVAGE THERAPY; SKIN MANIFESTATION; STEM CELL; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER PATIENT; CANCER RISK; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; MEDICAL HISTORY; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SECONDARY PREVENTION;

EID: 0036382721     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262001-00001     Document Type: Review

References (108)

1. Webster J, Lyman GH. Use of G-CSF to sustain dose intensity in breast cancer patients receiving adjuvant chemotherapy: a pilot study. Cancer Control 1996; 3: 519-23
2. Lyman G, Kuderer N, Greene J, et al. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998; 34: 1857-64
3. Bodey GP, Buckley M, Sathe YS. et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-40
4. Westermann AM, Taal BG, Swart M, et al. Sequence-dependent toxicity profile in modified famtx (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study. Pharmacol Res 2000; 42: 151-6
5. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000; 18: 3558-85
6. Blackwell S, Crawford J. Filgrastim (r-metHuG-CSF) in the chemotherapy setting. In: Morstyn G, Dexter T, editors. Filgrastim (r-metHuG-CSF) in clinical practice. New York: Marcel Dekker, 1994: 103-16
7. Madani TA. Clinical infections and bloodstream isolates associated with fever in patients undergoing chemotherapy for acute myeloid leukemia. Infection 2000; 28: 367-73
8. Gaur AH, Patrick CC, McCullers JA, et al. Bacillus cereus bacteremia and meningitis in immunocompromised children. Clin Infect Dis 2001; 32: 1456-62
9. Rodriguez-Adrian L, Grazziutti M, Rex J, et al. The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis 1998; 26: 1270-8
10. Freyer G, Ligneau B, Trillet-Lenoir V. Colony-stimulating factors in the prevention of solid tumours induced by chemotherapy in patients with febrile neutropenia. Int J Antimicrob Agents 1998; 10: 3-9
11. Freifeld AG, Pizzo PA, Walsh TJ, et al. Infection in the cancer patient. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice in oncology. Philadelphia: Lippincott, 1997: 2659-99
12. Grever HR, Chabner B. Cancer drug discovery and development. In: De Vita VT, Hellman S, Rosenberg SA, editors: Cancer: principles and practice in oncology. Philadelphia: Lippincott, 1997: 385-94
13. Klastersky J. Febrile neutropenia. Curr Opin Oncol 1993; 5: 625-32
14. Johnston E, Crawford J. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. Semin Oncol 1998; 25: 552-61
15. Pizzo PA, Hawthorn JW, Heimenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with neutropenia and fever. N Engl J Med 1986; 315: 552-8
16. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341: 305-11
17. Ad Hoc Colony-Stimulating Factor Guidelines Expert Panel. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471-508
18. Jacobson MA, Liu RC, Davies D, et al. Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection. Arch Intern Med 1997; 157: 1825-31
19. Ahkee S, Srinath L, Ramirez J. Community-acquired pneumonia in the elderly: association of mortality with lack of fever and leukocytosis. South Med J 1997; 90: 296-8
20. Voog E, Bienvenu J, Warzocha K, et al. Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system. J Clin Oncol 2000; 18: 325-31
21. Buchner T, Hiddemann W, Wormann B, et al. Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects. Semin Oncol 1997; 24: 124-31
22. Costa JJ. Updates on cells and cytokines: the therapeutic use of hematopoietic growth factors. J Allergy Clin Immunol 1998; 101: 1-6
23. Boclek RG, Armitage JO. Hematopoietic growth factors. CA Cancer J Clin 1996; 46: 165-84
24. Gerber A, Struy H, Weiss G, et al. Effect of granulocyte colony-stimulating factor treatment on ex vivo neutrophil functions in nonneutropenic surgical intensive care patients. J Interferon Cytokine Res 2000; 20: 1083-90
25. Ishikawa K, Tanaka H, Matsuoka T, et al. Recombinant human granulocyte colony-stimulating factor attenuates inflammatory responses in septic patients with neutropenia. J Trauma 1998; 44: 1047-54
26. Wenisch C, Werkgartner T, Sailer H, et al. Effect of preoperative prophylaxis with filgrastim in cancer neck dissection. Eur J Clin Invest 2000; 30: 460-6
27. Chuang PI, Yee E, Karsan A, et al. A1 is a constitutive and inducible Bcl-2 homologue in mature human neutrophils. Biochem Biophys Res Commun 1998; 249: 361-5
28. Lyman GH, Crawford J, Dale D, et al. Clinical prediction models for febrile neutropenia (FN) and relative dose intensity (RDI) in patients receiving adjuvant breast cancer chemotherapy [abstract #1571]. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12-15; San Francisco (CA)
29. Zelenetz AD, Reider PA, Delgado DJ. Review of patterns of care among community physicians in intermediate grade NHL (IGL) reveals significantly greater planned and delivered dose attenuation in older patients [abstract #588]. Presented at the American Society of Hematology; 2000 Dec 1-5; 2000, San Francisco (CA)
30. Picozzi VJ, Pohlman BL, Morrison VA, et al. Patterns of chemotherapy administration in patients with intermediate-grade non-hodgkins lymphoma. Oncology 2001; 15: 1296-306
31. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991; 325: 164-70
32. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 3: 19-24
33. Roche H, Chevallier B, Chollet P, et al. Lenograstim prevents morbidity from FEC-HD chemotherapy of inflammatory breast cancer. Ann Oncol 1994: 5: 91
34. Pentengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80: 1430-6
35. Zinzani PL. Randomized multicenter trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1994; 84: 163
36. Curreli L, Lampis B, Bianchi A, et al. Role of G-CSF in reducing rates, duration and morbidity of chemotherapy-induced febrile neutropenia. Br J Haematol 1996; 93: 270
37. Hamm JT, Schiller JH, Oken MM, et al. Granulocyte-macrophage colony stimulating factor in small cell carcinoma of the lung: Preliminary analysis of a randomized controlled trial [abstract #878]. Proceedings of the American Society of Clinical Oncology; 1991; 10: 255
38. Yau JC, Neidhart JA, Triozzi P, et al. Randomized placebo-controlled trial of granulocyte-macrophage colony stimulating factor support for dose intensive cyclophosphamide, etoposide, and cisplatin. Am J Hematol 1996; 51: 281-95
39. Barjorin D, Nichols CR, Schmoll HJ, et al. Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. J Clin Oncol 1995; 13: 79-86
40. Bunn PA, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995; 13: 1632-41
41. Weaver CH, Schulman KA, Wilson-Relyea B, et al. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 2000; 18: 43-53
42. Weaver CH, Buckner CD, Curtis LH, et al. Economic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim after myelosuppressive chemotherapy. Bone Marrow Transplant 2002; 29: 159-64
43. Milkovich G, Moleski R, Reitan J, et al. Comparative safety of filgrastim versus sargramostim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy 2000; 20: 1432-40
44. Gruson D, Hilbert G, Vargas F, et al. Impact of colony-stimulating factor therapy on clinical outcome and frequency rate of nosocomial infections in intensive care unit neutropenic patients. Crit Care Med 2000; 28: 3155-60
45. Bennett CL, Smith TJ, Weeks JC, et al. Use of hematopoietic colony-stimulating factors: the American society of clinical oncology survey: the health services research committee of the American Society of Clinical Oncology. J Clin Oncol 1996; 14: 2511-20
46. Bennett CL, Weeks JA, Somerfield MR, et al. Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol 1999; 17: 3676-81
47. Tamura K. Use of granulocyte colony-stimulating factor (G-CSF) in clinical practice in Fukuoka City area in Japan. Fukuoka Igaku Zasshi 1999; 90: 279-85
48. Trudeau ME. Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study. Oncology 2001; 15: 7-13
49. Moore T, Shiftan TA, Knight CA, et al. A prospective trial assessing a risk model for filgrastim use on dose intensity (DI) in the adjuvant treatment of stage I-III breast cancer patients (BCP) [abstract #1778]. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12-15; San Francisco (CA) 2001
50. Crawford J, Kreisman H, Garewal H, et al. The impact of filgrastim schedule variation on hematopoietic recovery post-chemotherapy. Ann Oncol 1997; 8: 1117-24
51. Koumakis G, Vassilomanolakis M, Barbounis V, et al. Optimal timing (preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Oncology 1999; 56: 28-35
52. Mayodormo JI, Rivera F, Diaz Puente MT, et al. Decreasing morbidity and cost of treating febrile neutropenia by adding G-CSF and GM-CSF to standard antibiotic therapy; results of a randomized trial [abstract #1510]. Proceedings of the American Society of Clinical Oncology; 1993 May 16-18; Orlando (FL). 1993.
53. Bennett CL, Stinson TJ, Laver JH, et al. Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making. Leuk Lymphoma 2000; 37: 65-70
54. Garcià-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001; 93: 31-8
55. Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Arch Intern Med 1988; 148: 2561-8
56. Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: a prospective two-center validation of a prediction rule. J Clin Oncol 1992; 10: 316-22
57. Maher D, Lieschke G, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo-controlled trial. Ann Med 1994; 121: 492-501
58. Riikonen P, Saarinen UM, Makipernaa A, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatr Infect Dis J 1994; 13: 197-202
59. Mayordomo JI, Rivera F, Diaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995; 87: 803-8
60. Anaissie E, Vartivarian S, Bodey GP, et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor Escherichia coli-derived in cancer patients with fever and neutropenia. Am J Med 1996; 100: 17-23
61. Vellenga E, Uyl-de Groot CA, de Wit R, et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol 1996; 14: 619-27
62. Mitchell PL, Morland B, Stevens MC, et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 1997; 15: 1163-70
63. Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998; 92: 1556-64
64. Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood 1998; 91: 3607-15
65. Rapoport B. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs standard in-patient care. Chemotherapy 1999; 45: 466-76
66. Gurney H, Dodwell D, Thatcher N, et al. Escalating drug delivery in cancer chemotherapy: a review of concepts and practice: Pt 2. Ann Oncol 1993; 4: 103-15
67. Dunn CJ, Goa KL. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs 2000; 59: 681-717
68. Lenograstim shows potential in a wide range of neutropenic and other indications. Drugs and Therapy Perspectives 2001; 17: 1-5
69. Woll PJ, Hodgetts J, Lomax L, et al. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor?. A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995; 13: 652-9
70. Bissett D, Jodrell D, Harnett AN, et al. Phase I study of accelerated FEC with granulocyte colony-stimulating factor (lenograstim) support. Br J Cancer 1995; 71: 1279-82
71. Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997; 89: 3974-9
72. Gisselbrecht C, Haioun C, Lepage E, et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma 1997; 25: 289-300
73. Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995; 13: 1564-71
74. Thatcher N, Girling DJ, Hopwood P, et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 2000; 18: 395-404
75. Wang X, Clowes C, Duarte R, et al. Expression of CD11b/CD18 on neutrophils after consolidation chemotherapy for acute myeloid leukemia and after high dose chemotherapy with autologous haematopoietic stem cell transplantation. Int J Oncol 2000; 17: 597-602
76. Canales MA, Arrieta R, Hernandez-Garcia MC, et al. Factors influencing collection and engraftment of CD34+ cells in patients with breast cancer following high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation. J Hematother Stem Cell Res 2000; 9: 103-9
77. Linch DC, Milligan DW, Winfield DA, et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 1997; 99: 933-8
78. Engelhardt M, Bertz H, Afting M, et al. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. J Clin Oncol 1999; 17: 2160-72
79. Szer J, Curtis DJ, Bardy PG, et al. The addition of allogeneic peripheral blood-derived progenitor cells to bone marrow for transplantation: results of a randomised clinical trial. Aust N Z J Med 1999; 29: 487-93
80. Weaver CH, Zhen B, Schwartzberg L, et al. A randomized trial of mobilization of peripheral blood stem cells with cyclophosphamide, etoposide, and granulocyte colony-stimulating factor with or without cisplatin in patients with malignant lymphoma receiving high-dose chemotherapy. Am J Clin Oncol 1998; 21: 408-12
81. Moskowitz CH, Glassman JR, Wuest D, et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311-6
82. Demetri G. The emergence of peripheral blood progenitor cells to support intensive chemotherapy for patients with breast cancer. Pharmacotherapy 1996; 16: 94S-100S
83. Gilbert C. Peripheral blood progenitor cell transplantation for breast cancer: pharmacoeconomic considerations. Pharmacotherapy 1996; 16: 101S-8S
84. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997; 90: 4710-8
85. Braess J, Voss S, Jahns-Streubel G, et al. The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity. Br J Haematol 2000; 110: 170-9
86. Usuki K, Urabe A, Masaoka T, et al. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Haematol 2002; 116: 103-12
87. Kantarjian HM, Estey E, O'Brien S, et al. Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission. Cancer 1993; 72: 2950-5
88. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547-61
89. Lehrnbecher T, Welte K. Haematopoietic growth factors in children with neutropenia. Br J Haematol 2002; 116: 28-56
90. Pui CH, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997; 336: 1781-7
91. Weiss MA, Glenn M, Maslak P, et al. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia 2000; 14: 577-82
92. Marotta G, Bigazzi C, Lenoci M, et al. Low-dose fludarabine and cyclophosphamide in elderly patients with B- cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica 2000; 85: 1268-70
93. Lyman GH. A predictive model for neutropenia associated with cancer chemotherapy. Pharmacotherapy 2000; 20: 104S-11S
94. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18: 2522-8
95. Dale DC. Hematopoietic growth factors for the treatment of severe chronic neutropenia. Stem Cells 1995; 2: 94-100
96. Foote M, Welch W. Biopharmaceutical drug development: Filgrastim (r-metHuG-CSF) use in patients with HIV infection. J Hematother Stem Cell Res 1999; 8: S3-8
97. Kuritzkes DR. Clinical experience with filgrastim in AIDS. J Hematother Stem Cell Res 1999; 8: S17-9
98. Remick SC, Sedransk N, Haase RF, et al. Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up. Am J Hematol 2001; 66: 178-88
99. Dubreuil-Lemaire ML, Gori A, Vittecoq D, et al. Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients. Eur J Haematol 2000; 65: 337-43
100. Hartung T. Granulocyte colony-stimulating factor: its potential role in infectious disease. AIDS 1999; 13: S3-9
101. Frumkin LR. Role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the treatment of patients with HIV infection. Curr Opin Hematol 1997; 4: 200-6
102. Slobod KS, Bennett TA, Freiden PJ, et al. Mobilization of CD34+ progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults. Blood 1996; 88: 3329-35
103. Nielsen SD, Dam-Larsen S, Nielsen C, et al. Recombinant human granulocyte colony-stimulating factor increases circulating CD34-positive cells in patients with AIDS. Ann Hematol 1997; 74: 215-20
104. Stoltz DA, Bagby GJ, Nelson S. Use of granulocyte colony-stimulating factor in the treatment of acute infectious diseases. Curr Opin Hematol 1997; 4: 207-12
105. Foster PF. The use of granulocyte colony-stimulating factor after liver transplantation. Transplantation 1995; 59: 1557-63
106. Fisher-Adams G, Wong Jr KK, Podsakoff G, et al. Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction. Blood 1996; 88: 492-504
107. Arafat WO, Casado E, Wang M, et al. Genetically modified CD34+ cells exert a cytotoxic bystander effect on human endothelial and cancer cells. Clin Cancer Res 2000; 6: 4442-8
108. Livingston RB, Ellis GK, Gralow JR, et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997; 15: 1395-400